Table 1 Patients clinical details

From: Genetic and pharmacological inhibition of microRNA-92a maintains podocyte cell cycle quiescence and limits crescentic glomerulonephritis

Gender	Age	Diagnosis	Group of patients	First episode/relapse	Treatment	Urinary protein (g/mmol creatinine)	eGFR (ml/min/1.73 m ² )
F	29	MCD	Control	Relapse	Corticosteroids	1.07	79
F	30	MCD	Control	Relapse	No treatment	0.19	73
M	66	MCD	Control	First episode	No treatment	0.56	55
F	31	MCD	Control	First episode	No treatment	NA	94
F	30	MN	Control	First episode	No treatment	0.08	89
M	46	MN	Control	First episode	No treatment	0.6	90
M	50	MN	Control	First episode	No treatment	>3	72
M	62	MPA	RPGN	First episode	No treatment	0.1	63
M	62	MPO-ANCA-positive	RPGN	First episode	No treatment	0.1	63
M	78	MPA	RPGN	First episode	Corticosteroids	0.23	39
M	78	PR3-ANCA-positive	RPGN	First episode	Corticosteroids	0.23	39
M	52	MPA	RPGN	First episode	No treatment	0.41	47
M	52	MPO-ANCA-positive	RPGN	First episode	No treatment	0.41	47
F	46	MPA	RPGN	First episode	No treatment	0.26	18
F	46	MPO-ANCA-positive	RPGN	First episode	No treatment	0.26	18
M	47	MPA	RPGN	First episode	No treatment	0.27	6
M	47	MPO-ANCA-positive	RPGN	First episode	No treatment	0.27	6
F	58	MPA	RPGN	First episode	No treatment	Traces	6
F	58	MPO-ANCA-positive	RPGN	First episode	No treatment	Traces	6
M	44	MPA	RPGN	First episode	No treatment	0.08	55
M	44	MPO-ANCA-positive	RPGN	First episode	No treatment	0.08	55
M	68	GPA	RPGN	First episode	Corticosteroids	0.15	58
M	68	PR3-ANCA-positive	RPGN	First episode	Corticosteroids	0.15	58
M	71	GPA	RPGN	First episode	No treatment	0.56	75
M	71	PR3-ANCA-positive	RPGN	First episode	No treatment	0.56	75
M	55	GPA	RPGN	Relapse	Corticosteroids	5	52
M	55	PR3-ANCA-positive	RPGN	Relapse	Corticosteroids	5	52
F	35	LN (class IV)	RPGN	Relapse	Corticosteroids	0.34	35
F	27	LN (class IV)	RPGN	Relapse	Corticosteroids	0.26	41
M	17	LN (class IV)	RPGN	First episode	No treatment	0.13	37
F	41	LN (class III)	RPGN	Relapse	Corticosteroids	0.19	25
F	25	LN (class III)	RPGN	First episode	No treatment	0.25	50

Patients’ characteristics at the time of the kidney biopsy used in the study. The eGFR is calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
MCD minimal change disease; MN membranous nephropathy; MPA microscopic polyangiitis; GPA granulomatosis with polyangiitis (GPA); ANCA anti-neutrophil cytoplasmic antibodies; MPO myeloperoxidase; PR3 proteinase 3; LN class III and class IV lupus nephritis, control for non-crescentic glomerular disease and RPGN for crescentic RPGN

Back to article page

Quick links

Search

Quick links